[O-34] Oral Session 34
Clinical trial and Regenerative medicine 2 E

[O-34-5] Natalizumab every 7 weeks dosing in 245 multiple sclerosis patients: efficacy and loss of PML risk

^○Takahiko Saida^1,2, Qi Hao^1,2, Michiko Yamauchi^1,2, Kyoko Saida^1,2,3 (1.Irino Clinic, Kansai Multiple Sclerosis Center, Japan, 2.Institute of Multiple Sclerosis Therapeutics, Japan, 3.Kyoto Hakuaikai Hospital, Dept. of Neurology)